Claims for Patent: 9,890,429

Summary for Patent: 9,890,429

Title:	Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
Abstract:	The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
Inventor(s):	Shipp; Margaret A. (Wellesley, MA), Monti; Stefano (Somerville, MA), Chapuy; Bjoern (Boston, MA), Rodig; Scott J. (Westwood, MA), Golub; Todd R. (Newton, MA)
Assignee:	Dana-Farber Cancer Institute, Inc. (Boston, MA) The Broad Institute, Inc. (Cambridge, MA)
Application Number:	14/381,004
Patent Claims:	1. A method of treating a human subject afflicted with diffuse large B-cell lymphoma (DLBCL), the method comprising: i) obtaining gene profiles of the human subject comprising an analysis of whether the human subject has an increased copy number of 1q23.3 and an increased level of expression of at least one of MDM4 and RFWD2, wherein the analysis is achieved by: a) determining the copy number of 1q23.3 and the level of expression of at least one of MDM4 and RFWD2 in a sample from the human subject, wherein the sample comprises DLBCL cells; b) determining the normal copy number of 1q23.3 and the level of expression of at least one of MDM4 and RFWD2 in a control sample; and c) comparing the copy number of 1q23.3 and the level of expression of at least one of MDM4 and RFWD2 detected in steps a) and b); and ii) administering a cyclin-dependent kinase (CDK) inhibitor to the human subject having increased copy number of 1q23.3 and increased level of expression of at least one of MDM4 and RFWD2 relative to the normal copy number and the level of expression in the control sample, wherein the CDK inhibitor is a small molecule that inhibits CDK1, CDK2, CDK4, CDK6, and CDK9. 2. The method of claim 1, wherein said human subject has at least twenty percent increase of the level of expression of at least one of MDM4 and RFWD2 relative to the normal level of expression in the control sample. 3. A method for treating diffuse large B-cell lymphoma (DLBCL) in a human subject, the method comprising: i) monitoring the progression of the DLBCL in the human subject, comprising: a) detecting in a sample from the human subject at a first point in time the copy number of 1q23.3 and the level of expression of at least one of MDM4 and RFWD2, wherein the sample comprises DLBCL cells; b) repeating step a) at a subsequent point in time; and c) comparing the copy number of 1q23.3 and the level of expression of at least one of MDM4 and RFWD2 detected in steps a) and b) to monitor the progression of the DLBCL; and ii) administering a cyclin-dependent kinase (CDK) inhibitor to the human subject having increased copy number of 1q23.3 and increased level of expression of at least one of MDM4 and RFWD2 relative to the first point in time at the subsequent point in time, wherein the CDK inhibitor is a small molecule that inhibits CDK1, CDK2, CDK4, CDK6, and CDK9. 4. The method of claim 3, wherein an at least twenty percent increase of the level of expression of at least one of MDM4 and RFWD2 in the sample at a subsequent point in time relative to in the sample at the first point in time indicates progression of the DLBCL. 5. The method of claim 3, wherein less than a twenty percent increase of the level of expression of at least one of MDM4 and RFWD2 in the sample at a subsequent point in time relative to in the sample at the first point in time indicates a lack of progression of the DLBCL. 6. The method of claim 3, wherein between the first point in time and the subsequent point in time, the subject has undergone treatment to ameliorate the DLBCL. 7. The method of claim 1, further comprising treating the human subject with one or more therapeutic agents selected from the group consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and a chemotherapeutic. 8. The method of claim 1, wherein the human subject has a copy number aberration (CNA) pattern involving another biomarker selected from the group of biomarkers consisting of CDKN2A, CDK6, TP53, KDM6B, RPL26, RBL2, BCL2L12, RB1, CDK2, CDK4, MDM2 and CCND3. 9. The method of claim 1, wherein the sample comprises cells, tissue, blood, buccal scrape, saliva, cerebrospinal fluid, stool, mucus, or bone marrow, obtained from the human subject. 10. The method of claim 1, wherein the copy number is assessed by microarray, quantitative PCR (qPCR), high-throughput sequencing, comparative genomic hybridization (CGH), or fluorescent in situ hybridization (FISH). 11. The method of claim 1, wherein the expression level of the at least one of MDM4 and RFWD2 is assessed by detecting the presence in the samples of a polynucleotide molecule encoding MDM4 or RFWD2. 12. The method of claim 11, wherein the polynucleotide molecule is a mRNA or cDNA. 13. The method of claim 11, wherein the step of detecting further comprises amplifying the polynucleotide molecule. 14. The method of claim 1, wherein the expression level of the at least one of MDM4 and RFWD2 is assessed by annealing a nucleic acid probe with a polynucleotide encoding MDM4 or RFWD2 in the samples under stringent hybridization conditions. 15. The method of claim 1, wherein the expression level of the at least one of MDM4 and RFWD2 is assessed by detecting the presence in the samples of a protein of MDM4 or RFWD2. 16. The method of claim 15, wherein the presence of said protein is detected using an antibody or an antigen binding fragment thereof which specifically binds with said protein. 17. The method of claim 1, wherein the human subject further has a copy loss at 17p13.1. 18. The method of claim 1, wherein the human subject further has copy number aberration (CNA) of at least one of 9q21.3, 19q13.42, 12q15, 6p21.32, 7q22.1, 13q14.2, and 16q12.2. 19. The method of claim 8, wherein the human subject further has copy number gain of at least one of CDK6, BCL2L12, CDK2, CDK4, MDM2, and CCND3. 20. The method of claim 8, wherein the human subject further has copy number loss of at least one of CDKN2A, TP53, KDM6B, RPL26, RBL2, and RB1.

Details for Patent 9,890,429

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-02-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2032-02-29